Related Experiment Video
Updated: Jun 11, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
CCR6 as a possible therapeutic target in psoriasis
Michael N Hedrick1, Anke S Lonsdorf, Sam T Hwang
1National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Molecular Immunology, Inflammation Biology Section, Bethesda, MD 20892, USA.
Expert Opinion on Therapeutic Targets
|July 16, 2010
Summary
Chemokine receptor CCR6 plays a key role in psoriasis pathogenesis. Inhibiting CCR6 could be a promising new therapeutic strategy for treating this chronic skin disease.
Area of Science:
- Dermatology and immunology
- Autoimmune skin diseases
- Inflammation and cellular signaling
Background:
- Psoriasis is a chronic autoimmune skin condition requiring novel treatments.
- Chemokine receptors, like CCR6, are crucial for leukocyte trafficking and are viable drug targets.
- CCR6 and its ligand CCL20 are significantly elevated in psoriatic skin, implicating them in disease development.
Purpose of the Study:
- To review the role of the IL-23/T(H)17 axis, specifically CCR6 and CCL20, in psoriasis.
- To explore the potential of CCR6 inhibition as a therapeutic approach for psoriasis.
Main Methods:
- Comprehensive literature review of studies from 2000 to present.
- Analysis of evidence linking CCR6 and CCL20 to psoriasis pathogenesis.
- Discussion of therapeutic implications of targeting CCR6.
Main Results:
- The IL-23/T(H)17 pathway is central to psoriasis inflammation.
- CCR6 and CCL20 are highly expressed in psoriatic lesions.
- CCR6 is essential for experimental models of psoriasis-like inflammation.
Conclusions:
- CCR6 is a significant factor in psoriasis pathogenesis.
- CCR6 inhibition presents a potential therapeutic avenue for psoriasis treatment.
- Further investigation into CCR6 as a drug target is warranted.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...